GlassScriptPhysician profile
Kara L Wollenweber
NPI 1811301310
$4,040.28
in general payments reported to CMS, 2019-2025
38 companies · $66.73 in 2025
The $66.73 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $561 · 2022: $1,306 · 2023: $1,114 · 2024: $992 · 2025: $66.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,164 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,164.11 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $994.56 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $579.33 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $456.15 | 2021-2024 | Farxiga, Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $234.74 | 2021-2024 | Spravato |
| Pfizer INC. | $187.72 | 2022-2024 | |
| Amgen INC. | $150.71 | 2021-2025 | Evenity, Prolia, Repatha |
| Jazz Pharmaceuticals INC. | $125.00 | 2022 | |
| Merck Sharp & Dohme LLC | $108.36 | 2021-2023 | Vaxneuvance, Pneumovax 23, Gardasil 9 |
| Amarin Pharma, INC. | $80.96 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $77.45 | 2021-2024 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $75.87 | 2021-2024 | Zoryve |
| Antares Pharma, INC. | $75.13 | 2023-2024 | Xyosted, Nocdurna, Tlando |
| Glaxosmithkline, LLC. | $63.87 | 2022-2023 | Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.91 | 2023-2024 | Ofev, Jardiance |
| Exact Sciences Corporation | $60.71 | 2023-2024 | Cologuard Collection Kit |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Wollenweber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.